POST-POLYCYTHEMIA VERA MYELOFIBROSIS (POST-PV MF)
Clinical trials for POST-POLYCYTHEMIA VERA MYELOFIBROSIS (POST-PV MF) explained in plain language.
Never miss a new study
Get alerted when new POST-POLYCYTHEMIA VERA MYELOFIBROSIS (POST-PV MF) trials appear
Sign up with your email to follow new studies for POST-POLYCYTHEMIA VERA MYELOFIBROSIS (POST-PV MF), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for rare bone marrow cancer? small trial tests add-on therapy
Disease control Recruiting nowThis early-stage study tests whether adding pelabresib to the standard drug ruxolitinib is safe for Japanese adults with myelofibrosis, a rare bone marrow disorder. Only 6 participants will be enrolled to check for side effects and how the drug behaves in the body. The goal is to…
Matched conditions: POST-POLYCYTHEMIA VERA MYELOFIBROSIS (POST-PV MF)
Phase: PHASE1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 05, 2026 12:07 UTC
-
5,000 patients join Long-Term study to unlock mysteries of rare blood cancers
Knowledge-focused Recruiting nowThis study is a long-term observation of 5,000 adults with myeloproliferative neoplasms (MPNs), a group of rare blood cancers. Researchers will collect health records, insurance data, and patient surveys over at least five years to track symptoms, treatments, and how the disease …
Matched conditions: POST-POLYCYTHEMIA VERA MYELOFIBROSIS (POST-PV MF)
Sponsor: MPN Research Foundation • Aim: Knowledge-focused
Last updated Jun 08, 2026 13:04 UTC